Enterprise Value
195.3M
Cash
304.4M
Avg Qtr Burn
-22.06M
Short % of Float
0.00%
Insider Ownership
0.48%
Institutional Own.
34.57%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Icosapent Etheyl (generic Vascepa) Details Cardiovascular Disease | Approved Update | |
Vascepa (icosapent ethyl) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Quarterly sales | |
Vascepa (icosapent ethyl) Details Infectious disease, COVID-19 | Failed Discontinued |